Nobel Biocare has announced that effective February 1, 2015, Tullio Di Dio will be appointed Chief Financial Officer, succeeding Oliver Walker, who has decided to leave the company to pursue his career interests outside Nobel Biocare.

Di Dio joins Nobel Biocare with 23 years of finance experience, including assignments at United Technologies, Roche, and during the past 12 years with Danaher. Most recently, Di Dio served as Vice President, Finance for Beckman Coulter EMEA. He played an important role in integrating Beckman Coulter into Danaher.  

Richard Laube, CEO of Nobel Biocare, said: “I wish to welcome Tullio Di Dio, who will provide valuable experience as Nobel Biocare integrates into Danaher. At the same time, I wish Oliver Walker much success in his new endeavors and would like to thank him for his efforts and contributions in helping to turn Nobel Biocare around and make it a more predictable and performing business during his two and a half years of service. Our finance team has become a significantly more capable and effective organization with his leadership.”